Targeting Neuroinflammation in Central Nervous System Diseases by Oral Delivery of Lipid Nanoparticles DOI Creative Commons
Yuan Zou, Jing Zhang, Longmin Chen

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(3), P. 388 - 388

Published: March 18, 2025

Neuroinflammation within the central nervous system (CNS) is a primary characteristic of CNS diseases, such as Parkinson’s disease, Alzheimer’s disease (AD), amyotrophic lateral sclerosis, and mental disorders. The excessive activation immune cells results in massive release pro-inflammatory cytokines, which subsequently induce neuronal death accelerate progression neurodegeneration. Therefore, mitigating neuroinflammation has emerged promising strategy for treatment diseases. Despite advancements drug discovery development novel therapeutics, effective delivery these agents to remains serious challenge due restrictive nature blood–brain barrier (BBB). This underscores need develop system. Recent studies have identified oral lipid nanoparticles (LNPs) approach efficiently deliver drugs across BBB treat neurological review aims comprehensively summarize recent LNPs designed controlled therapeutic modulation diseases through administration. Furthermore, this addresses mechanisms by overcome biological barriers evaluate their clinical implications efficacy context systems. Specifically, it focuses on LNP formulations that facilitate administration, exploring potential enhance bioavailability, improve targeting precision, alleviate or manage symptoms associated with range

Language: Английский

Lipid Nanoparticles for mRNA Delivery in Cancer Immunotherapy DOI
Yasir Alshehry, Xiang Liu,

Wenhua Li

et al.

The AAPS Journal, Journal Year: 2025, Volume and Issue: 27(3)

Published: March 18, 2025

Language: Английский

Citations

0
Targeting Neuroinflammation in Central Nervous System Diseases by Oral Delivery of Lipid Nanoparticles DOI Creative Commons
Yuan Zou, Jing Zhang, Longmin Chen

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(3), P. 388 - 388

Published: March 18, 2025

Neuroinflammation within the central nervous system (CNS) is a primary characteristic of CNS diseases, such as Parkinson’s disease, Alzheimer’s disease (AD), amyotrophic lateral sclerosis, and mental disorders. The excessive activation immune cells results in massive release pro-inflammatory cytokines, which subsequently induce neuronal death accelerate progression neurodegeneration. Therefore, mitigating neuroinflammation has emerged promising strategy for treatment diseases. Despite advancements drug discovery development novel therapeutics, effective delivery these agents to remains serious challenge due restrictive nature blood–brain barrier (BBB). This underscores need develop system. Recent studies have identified oral lipid nanoparticles (LNPs) approach efficiently deliver drugs across BBB treat neurological review aims comprehensively summarize recent LNPs designed controlled therapeutic modulation diseases through administration. Furthermore, this addresses mechanisms by overcome biological barriers evaluate their clinical implications efficacy context systems. Specifically, it focuses on LNP formulations that facilitate administration, exploring potential enhance bioavailability, improve targeting precision, alleviate or manage symptoms associated with range

Language: Английский

Citations

0